The 200-Rep Trial: 200 repetitions of isolated muscle contractions for partially-paralysed muscles
The 200-Rep trial is a pragmatic multi-centre, single-blinded randomised controlled trial. The primary aim of the trial is to compare the effectiveness of repeated contractions of isolated muscles combined with usual care, versus usual care alone for increasing strength in very weak partially-paralysed muscles of people with recent spinal cord injury (SCI).
The secondary aims are to determine the effectiveness of repeated contractions of isolated muscles combined with usual care versus usual care alone on:
The participants are included in the trial if they:
The participants are excluded from the trial if they:
The primary outcome is strength at 8 weeks. One target muscle group for each participant is selected from the following groups of muscles: the elbow flexors, elbow extensors, wrist flexors, wrist extensors, knee flexors, knee extensor muscles, ankle dorsiflexors or ankle plantar flexors. Eligible participants are randomised to one of two groups, either the Treatment group or the Control group.
Participants allocated to the Treatment group are required to do 200 repetitions of isolated contractions of the target muscle group on one side of their body only (under supervision), however both sides of the body continue to receive “usual care”. Participants allocated to the Control group received usual care alone.
Total 120 participants from Seven different centres from Australia and Asia
Baseline and follow-up assessments:
Participants are measured once prior to the commencement of the trial and once 8 weeks after randomisation. Baseline assessments are conducted prior to randomization. Follow-up assessments are conducted by the same blinded assessors 8 weeks after randomisation (within a 1-week window) regardless of treatment adherence. Participants are told not to discuss their group allocation with the blinded assessor and the success of blinding is being measured. The 8-week assessments are conducted face-to-face.
Update: The trial was finished in early 2019. Click link to see the full article: https://www.nature.com/articles/s41393-020-0439-1